Alzheimer's drug ALZ-801 tested Long-Term in High-Risk group
Disease control
Terminated
This study looked at the long-term safety and effects of ALZ-801, a tablet taken twice daily, in 163 people with early Alzheimer's disease who have the APOE4/4 gene. Participants had already completed a previous phase 3 study. The goal was to see if the drug could slow cognitive …
Phase: PHASE3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC